Tumor hypoxia is a well-established biological phenomenon that affects the curability of solid tumors, regardless of treatment modality. Especially for head and neck cancer patients, tumor hypoxia is linked to poor patient outcomes. Given the biological problems associated with tumor hypoxia, the goal for clinicians has been to identify moderately to severely hypoxic tumors for differential treatment strategies. The “gold standard” for detecting and characterizing of tumor hypoxia are the invasive polarographic electrodes. Several less invasive hypoxia assessment techniques have also shown promise for hypoxia assessment. The widespread incorporation of hypoxia information in clinical tumor assessment is severely impeded by several factors, including regulatory hurdles and unclear correlation with potential treatment decisions. There is now an acute need for approved diagnostic technologies for determining the hypoxia status of cancer lesions, as it would enable clinical development of personalized, hypoxia-based therapies, which will ultimately improve outcomes. A number of different techniques for assessing tumor hypoxia have evolved to replace polarographic pO2 measurements for assessing tumor hypoxia. Several of these modalities, either individually or in combination with other imaging techniques, provide functional and physiological information of tumor hypoxia that can significantly improve the course of treatment. The assessment of tumor hypoxia will be valuable to radiation oncologists, surgeons, and biotechnology and pharmaceutical companies who are engaged in developing hypoxia-based therapies or treatment strategies. Antioxid. Redox Signal. 21, 1516–1554.
AdamMF, GabalskiEC, BlochDA, OehlertJW, BrownJM, ElsaidAA, PintoHA, and TerrisDJ. Tissue oxygen distribution in head and neck cancer patients. Head Neck, 21: 146–153, 1999.
2.
AdamsGE, AhmedI, SheldonPW, and StratfordIJ. Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. Br J Cancer, 49: 571–577, 1984.
3.
AirleyRE, LoncasterJ, RaleighJA, HarrisAL, DavidsonSE, HunterRD, WestCM, and StratfordIJ. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer, 104: 85–91, 2003.
4.
Aquino-ParsonsC, LuoC, VikseCM, and OlivePL. Comparison between the comet assay and the oxygen microelectrode for measurement of tumor hypoxia. Radiother Oncol, 51: 179–185, 1999.
5.
ArteelGE, ThurmanRG, YatesJM, and RaleighJA. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer, 72: 889–895, 1995.
6.
BabaY, NoshoK, ShimaK, IraharaN, ChanAT, MeyerhardtJA, ChungDC, GiovannucciEL, FuchsCS, and OginoS. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol, 176: 2292–2301, 2010.
7.
BacheM, KapplerM, SaidHM, StaabA, and VordermarkD. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr Med Chem, 15: 322–338, 2008.
8.
BacheM, KapplerM, WichmannH, RotS, HahnelA, GreitherT, SaidHM, KotzschM, WurlP, TaubertH, and VordermarkD. Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer, 10: 132, 2010.
9.
BacheM, ReddemannR, SaidHM, HolzhausenHJ, TaubertH, BeckerA, KuhntT, HansgenG, DunstJ, and VordermarkD. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys, 66: 1481–1487, 2006.
10.
BaskenNE and GreenMA. Cu(II) bis(thiosemicarbazone) radiopharmaceutical binding to serum albumin: further definition of species dependence and associated substituent effects. Nucl Med Biol, 36: 495–504, 2009.
11.
BaudeletC and GallezB. How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors?. Magn Reson Med, 48: 980–986, 2002.
12.
BeasleyNJ, LeekR, AlamM, TurleyH, CoxGJ, GatterK, MillardP, FuggleS, and HarrisAL. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res, 62: 2493–2497, 2002.
13.
BennewithKL and DedharS. Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer, 11: 504, 2011.
14.
BentzenL, KeidingS, NordsmarkM, FalborgL, HansenSB, KellerJ, NielsenOS, and OvergaardJ. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol, 67: 339–344, 2003.
15.
BetenskyRA, LouisDN, and CairncrossJG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol, 20: 2495–2499, 2002.
16.
BetofAS, RabbaniZN, HardeeME, KimSJ, BroadwaterG, BentleyRC, SnyderSA, VujaskovicZ, OosterwijkE, HarrisLN, HortonJK, DewhirstMW, and BlackwellKL. Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. Br J Cancer, 106: 916–922, 2012.
17.
BollineniVR, WiegmanEM, PruimJ, GroenHJ, and LangendijkJA. Hypoxia imaging using positron emission tomography in non-small cell lung cancer: implications for radiotherapy. Cancer Treat Rev, 38: 1027–1032, 2012.
18.
BourkeVA, ZhaoD, GilioJ, ChangCH, JiangL, HahnEW, and MasonRP. Correlation of radiation response with tumor oxygenation in the Dunning prostate R3327-AT1 tumor. Int J Radiat Oncol Biol Phys, 67: 1179–1186, 2007.
19.
BoushelR, LangbergH, OlesenJ, Gonzales-AlonzoJ, BulowJ, and KjaerM. Monitoring tissue oxygen availability with near infrared spectroscopy (NIRS) in health and disease. Scand J Med Sci Sports, 11: 213–222, 2001.
20.
BowenSR, van der KogelAJ, NordsmarkM, BentzenSM, and JerajR. Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. Nucl Med Biol, 38: 771–780, 2011.
21.
BrizelDM, DodgeRK, CloughRW, and DewhirstMW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol, 53: 113–117, 1999.
22.
BrizelDM, ProsnitzRG, HunterS, FisherSR, CloughRL, DowneyMA, and ScherRL. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys, 58: 1418–1423, 2004.
23.
BrizelDM, ScullySP, HarrelsonJM, LayfieldLJ, BeanJM, ProsnitzLR, and DewhirstMW. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res, 56: 941–943, 1996.
24.
BrocktonN, DortJ, LauH, HaoD, BrarS, KlimowiczA, PetrilloS, DiazR, DollC, and MaglioccoA. High stromal carbonic anhydrase IX expression is associated with decreased survival in P16-negative head-and-neck tumors. Int J Radiat Oncol Biol Phys, 80: 249–257, 2011.
25.
BrownJM. The hypoxic cell: a target for selective cancer therapy—eighteenth and Bruce F. Cain Memorial Award lecture. Cancer Res, 59: 5863–5870, 1999.
26.
BrownJM, DiehnM, and LooBWJr. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys, 78: 323–327, 2010.
27.
BrownJM and WilsonWR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer, 4: 437–447, 2004.
28.
BruehlmeierM, RoelckeU, SchubigerPA, and AmetameySM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med, 45: 1851–1859, 2004.
29.
BurgmanP, OdonoghueJA, HummJL, and LingCC. Hypoxia-Induced increase in FDG uptake in MCF7 cells. J Nucl Med, 42: 170–175, 2001.
30.
BuskM, HorsmanMR, JakobsenS, KeidingS, van der KogelAJ, BussinkJ, and OvergaardJ. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys, 70: 1202–1212, 2008.
31.
CanningMT, PostovitLM, ClarkeSH, and GrahamCH. Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells. Exp Cell Res, 267: 88–94, 2001.
32.
CarmelietP and JainRK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov, 10: 417–427, 2011.
33.
CaseyG. Oxygen transport and the use of pulse oximetry. Nurs Stand, 15: 46–53, 2001.
34.
CernigliaGJ, PoreN, TsaiJH, SchultzS, MickR, ChoeR, XingX, DurduranT, YodhAG, EvansSM, KochCJ, HahnSM, QuonH, SehgalCM, LeeWM, and MaityA. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One, 4: e6539, 2009.
35.
ChaeSS, KamounWS, FarrarCT, KirkpatrickND, NiemeyerE, de GraafAM, SorensenAG, MunnLL, JainRK, and FukumuraD. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res, 16: 3618–3627, 2010.
36.
ChangJ, WenB, KazanzidesP, ZanzonicoP, FinnRD, FichtingerG, and LingCC. A robotic system for 18F-FMISO PET-guided intratumoral pO2 measurements. Med Phys, 36: 5301–5309, 2009.
37.
ChangQ, JurisicaI, DoT, and HedleyDW. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res, 71: 3110–3120, 2011.
38.
ChaoKS, BoschWR, MuticS, LewisJS, DehdashtiF, MintunMA, DempseyJF, PerezCA, PurdyJA, and WelchMJ. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys, 49: 1171–1182, 2001.
39.
ChaoKS, OzyigitG, TranBN, CengizM, DempseyJF, and LowDA. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys, 55: 312–321, 2003.
40.
ChapmanJD, FrankoAJ, and SharplinJ. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer, 43: 546–550, 1981.
41.
ChenL, ZhangZ, KolbHC, WalshJC, ZhangJ, and GuanY. 18F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with (18)F-FMISO. Nucl Med Commun, 33: 1096–1102, 2012.
42.
ChenYJ, WeiYY, ChenHT, FongYC, HsuCJ, TsaiCH, HsuHC, LiuSH, and TangCH. Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol, 221: 98–108, 2009.
43.
ChiaSK, WykoffCC, WatsonPH, HanC, LeekRD, PastorekJ, GatterKC, RatcliffeP, and HarrisAL. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol, 19: 3660–3668, 2001.
44.
ChicheJ, Brahimi-HornMC, and PouyssegurJ. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med, 14: 771–794, 2010.
45.
ChoeR and YodhAG. Diffuse Optical Tomography of the Breast. Valencia, CA: American Scientific Publishers, 2006, p. 600.
46.
ChongLM and HuntMA. IMRT for Head and Neck Cancer. Madison, WI: Medical Physics Publishing, 2003.
47.
ChopraS, FoltzWD, MilosevicMF, ToiA, BristowRG, MenardC, and HaiderMA. Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. Int J Radiat Biol, 85: 805–813, 2009.
48.
ChoykePL, DwyerAJ, and KnoppMV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging, 17: 509–520, 2003.
49.
ClarkLCJr., AckermanJL, ThomasSR, MillardRW, HoffmanRE, PrattRG, Ragle-ColeH, KinseyRA, and JanakiramanR. Perfluorinated organic liquids and emulsions as biocompatible NMR imaging agents for 19F and dissolved oxygen. Adv Exp Med Biol, 180: 835–845, 1984.
50.
ColletG, SkrzypekK, GrillonC, MatejukA, Hafni-RhabiBE, LamerantN, and KiedaC. Hypoxia control to normalize pathologic angiogenesis: potential role for endothelial precursor cells and miRNAs regulation. Vascul Pharmacol, 56: 252–261, 2012.
51.
CollingridgeDR, PiepmeierJM, RockwellS, and KniselyJP. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol, 53: 127–131, 1999.
52.
ConleySJ, GheordunescuE, KakaralaP, NewmanB, KorkayaH, HeathAN, ClouthierSG, and WichaMS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A, 109: 2784–2789.
53.
CooperRA, CarringtonBM, LoncasterJA, ToddSM, DavidsonSE, LogueJP, LuthraAD, JonesAP, StratfordI, HunterRD, and WestCM. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol, 57: 53–59, 2000.
54.
DaiN, BaoQ, LuA, and LiJ. Protein expression of osteopontin in tumor tissues is an independent prognostic indicator in gastric cancer. Oncology, 72: 89–96, 2007.
55.
DanhierF, DanhierP, MagotteauxN, De PreterG, UcakarB, KarroumO, JordanB, GallezB, and PreatV. Electron paramagnetic resonance highlights that the oxygen effect contributes to the radiosensitizing effect of paclitaxel. PLoS One, 7: e40772, 2012.
56.
DavdaS and BezabehT. Advances in methods for assessing tumor hypoxia in vivo: implications for treatment planning. Cancer Metastasis Rev, 25: 469–480, 2006.
57.
DawsonLA, AnzaiY, MarshL, MartelMK, PaulinoA, ShipJA, and EisbruchA. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys, 46: 1117–1126, 2000.
58.
DeanM, FojoT, and BatesS. Tumour stem cells and drug resistance. Nat Rev Cancer, 5: 275–284, 2005.
59.
DehdashtiF, GrigsbyPW, LewisJS, LaforestR, SiegelBA, and WelchMJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med, 49: 201–205, 2008.
60.
DehdashtiF, GrigsbyPW, MintunMA, LewisJS, SiegelBA, and WelchMJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys, 55: 1233–1238, 2003.
61.
DehdashtiF, MintunMA, LewisJS, BradleyJ, GovindanR, LaforestR, WelchMJ, and SiegelBA. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging, 30: 844–850, 2003.
62.
DenceCS, PondeDE, WelchMJ, and LewisJS. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nucl Med Biol, 35: 713–720, 2008.
63.
DenglerJ, FrenzelC, VajkoczyP, WolfS, and HornP. Cerebral tissue oxygenation measured by two different probes: challenges and interpretation. Intensive Care Med, 37: 1809–1815, 2011.
64.
DentJG and NetterKJ. Errors in oxygen tension measurements caused by halothane. Br J Anaesth, 48: 195–197, 1976.
65.
Di MartinoEF, GagelB, SchrammO, ManeschiP, and WesthofenM. Evaluation of tumor oxygenation by color duplex sonography: a new approach. Otolaryngol Head Neck Surg, 132: 765–769, 2005.
66.
DiehnM, ChoRW, LoboNA, KaliskyT, DorieMJ, KulpAN, QianD, LamJS, AillesLE, WongM, JoshuaB, KaplanMJ, WapnirI, DirbasFM, SomloG, GarberoglioC, PazB, ShenJ, LauSK, QuakeSR, BrownJM, WeissmanIL, and ClarkeMF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature, 458: 780–783, 2009.
67.
DietzA, VanselowB, RudatV, ConradtC, WeidauerH, KallinowskiF, and DollnerR. Prognostic impact of reoxygenation in advanced cancer of the head and neck during the initial course of chemoradiation or radiotherapy alone. Head Neck, 25: 50–58, 2003.
68.
DietzDW, DehdashtiF, GrigsbyPW, MalyapaRS, MyersonRJ, PicusJ, RitterJ, LewisJS, WelchMJ, and SiegelBA. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum, 51: 1641–1648, 2008.
69.
DingsRP, LorenM, HeunH, McNielE, GriffioenAW, MayoKH, and GriffinRJ. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res, 13: 3395–3402, 2007.
70.
DirixP, VandecaveyeV, De KeyzerF, StroobantsS, HermansR, and NuytsS. Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med, 50: 1020–1027, 2009.
71.
DischeS, MachinD, and ChassagneD. A trial of Ro 03–8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother Oncol, 26: 93–103, 1993.
72.
DischeS, SaundersMI, BennettMH, DunphyEP, Des RochersC, StratfordMR, MinchintonAI, and WardmanP. A comparison of the tumour concentrations obtainable with misonidazole and Ro 03–8799. Br J Radiol, 59: 911–917, 1986.
73.
DonaldsonSB, BettsG, BoningtonSC, HomerJJ, SlevinNJ, KershawLE, ValentineH, WestCM, and BuckleyDL. Perfusion estimated with rapid dynamic contrast-enhanced magnetic resonance imaging correlates inversely with vascular endothelial growth factor expression and pimonidazole staining in head-and-neck cancer: a pilot study. Int J Radiat Oncol Biol Phys, 81: 1176–1183, 2011.
74.
DossM, ZhangJJ, BelangerMJ, StubbsJB, HostetlerED, AlpaughK, KolbHC, and YuJQ. Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT. Nucl Med Commun, 31: 1016–1024, 2010.
75.
DuboisLJ, LieuwesNG, JanssenMH, PeetersWJ, WindhorstAD, WalshJC, KolbHC, OllersMC, BussinkJ, van DongenGA, van der KogelA, and LambinP. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A, 108: 14620–14625, 2011.
76.
DunphyI, VinogradovSA, and WilsonDF. Oxyphor R2 and G2: phosphors for measuring oxygen by oxygen-dependent quenching of phosphorescence. Anal Biochem, 310: 191–198, 2002.
77.
DunstJ, StadlerP, BeckerA, LautenschlagerC, PelzT, HansgenG, MollsM, and KuhntT. Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol, 179: 521–526, 2003.
78.
EichhornME, StriethS, LuedemannS, KleespiesA, NothU, PassonA, BrixG, JauchKW, BrunsCJ, and DellianM. Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment. Cancer Biol Ther, 7: 1006–1013, 2008.
79.
ElasM, AhnKH, ParascaA, BarthED, LeeD, HaneyC, and HalpernHJ. Electron paramagnetic resonance oxygen images correlate spatially and quantitatively with Oxylite oxygen measurements. Clin Cancer Res, 12: 4209–4217, 2006.
80.
ElasM, BellR, HleihelD, BarthED, McFaulC, HaneyCR, BielanskaJ, PustelnyK, AhnKH, PelizzariCA, KocherginskyM, and HalpernHJ. Electron paramagnetic resonance oxygen image hypoxic fraction plus radiation dose strongly correlates with tumor cure in FSa fibrosarcomas. Int J Radiat Oncol Biol Phys, 71: 542–549, 2008.
81.
ElasM, MagwoodJM, ButlerB, LiC, WardakR, BarthED, EpelB, RubinsteinS, PelizzariCA, WeichselbaumRR, and HalpernHJ. EPR Oxygen Images Predict Tumor Control by a 50% Tumor Control Radiation Dose. Cancer Res, 73: 5328–5335, 2013.
82.
EriksenJG and OvergaardJ. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiother Oncol, 83: 383–388, 2007.
83.
EschmannSM, PaulsenF, BedeshemC, MachullaHJ, HehrT, BambergM, and BaresR. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol, 83: 406–410, 2007.
84.
EschmannSM, PaulsenF, ReimoldM, DittmannH, WelzS, ReischlG, MachullaHJ, and BaresR. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med, 46: 253–260, 2005.
85.
EsipovaTV, KaragodovA, MillerJ, WilsonDF, BuschTM, and VinogradovSA. Two new “protected” oxyphors for biological oximetry: properties and application in tumor imaging. Anal Chem, 83: 8756–8765, 2011.
86.
EvansSM, DuKL, ChalianAA, MickR, ZhangPJ, HahnSM, QuonH, LustigR, WeinsteinGS, and KochCJ. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int J Radiat Oncol Biol Phys, 69: 1024–1031, 2007.
87.
EvansSM, FrakerD, HahnSM, GleasonK, JenkinsWT, JenkinsK, HwangWT, ZhangP, MickR, and KochCJ. EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys, 64: 922–927, 2006.
88.
EvansSM, HahnS, PookDR, JenkinsWT, ChalianAA, ZhangP, StevensC, WeberR, WeinsteinG, BenjaminI, MirzaN, MorganM, RubinS, McKennaWG, LordEM, and KochCJ. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res, 60: 2018–2024, 2000.
89.
EvansSM, HahnSM, MagarelliDP, ZhangPJ, JenkinsWT, FrakerDL, HsiRA, McKennaWG, and KochCJ. Hypoxia in human intraperitoneal and extremity sarcomas. Int J Radiat Oncol Biol Phys, 49: 587–596, 2001.
90.
EvansSM, JenkinsKW, ChenHI, JenkinsWT, JudyKD, HwangWT, LustigRA, JudkinsAR, GradyMS, HahnSM, and KochCJ. The relationship among hypoxia, proliferation, and outcome in patients with de novo glioblastoma: a pilot study. Transl Oncol, 3: 160–169, 2010.
91.
EvansSM, JudyKD, DunphyI, JenkinsWT, NelsonPT, CollinsR, WileytoEP, JenkinsK, HahnSM, StevensCW, JudkinsAR, PhillipsP, GeoergerB, and KochCJ. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res, 64: 1886–1892, 2004.
92.
FrederiksenLJ, SiemensDR, HeatonJP, MaxwellLR, AdamsMA, and GrahamCH. Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. J Urol, 170: 1003–1007, 2003.
93.
GaertnerFC, SouvatzoglouM, BrixG, and BeerAJ. Imaging of hypoxia using PET and MRI. Curr Pharm Biotechnol, 13: 552–570, 2012.
94.
GagelB, DiMartinoE, SchrammO, PinkawaM, PirothM, DemirelC, ManeschiP, StanzelS, AsadpourB, WesthofenM, and EbleMJ. Contrast-enhanced color duplex sonography (CDS): an alternative for the evaluation of therapy-relevant tumor oxygenation?. Strahlenther Onkol, 182: 604–609, 2006.
95.
GagelB, PirothM, PinkawaM, ReinartzP, ZimnyM, KaiserHJ, StanzelS, AsadpourB, DemirelC, HamacherK, CoenenHH, ScholbachT, ManeschiP, DiMartinoE, and EbleMJ. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia?. BMC Cancer, 7: 113, 2007.
96.
GagelB, ReinartzP, DimartinoE, ZimnyM, PinkawaM, ManeschiP, StanzelS, HamacherK, CoenenHH, WesthofenM, BullU, and EbleMJ. pO2 Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2′-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol, 180: 616–622, 2004.
97.
GallezB, BaudeletC, and JordanBF. Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications. NMR Biomed, 17: 240–262, 2004.
98.
GammonL, BiddleA, HeywoodHK, JohannessenAC, and MackenzieIC. Sub-sets of cancer stem cells differ intrinsically in their patterns of oxygen metabolism. PLoS One, 8: e62493.
99.
Garcia-ParraR, WoodD, ShahRB, SiddiquiJ, HussainH, ParkH, DesmondT, MeyerC, and PiertM. Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques. Eur J Nucl Med Mol Imaging, 38: 1816–1823, 2011.
100.
GatenbyRA, KesslerHB, RosenblumJS, CoiaLR, MoldofskyPJ, HartzWH, and BroderGJ. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys, 14: 831–838, 1988.
101.
GaustadJV, SimonsenTG, LeinaasMN, and RofstadEK. Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts. BMC Cancer, 12: 388, 2012.
102.
GiacciaAJ. Hypoxic stress proteins: survival of the fittest. Semin Radiat Oncol, 6: 46–58, 1996.
103.
GiatromanolakiA and HarrisAL. Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. Anticancer Res, 21: 4317–4324, 2001.
104.
GoethalsL, DebucquoyA, PerneelC, GeboesK, EctorsN, De SchutterH, PenninckxF, McBrideWH, BeggAC, and HaustermansKM. Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys, 65: 246–254, 2006.
105.
GraeberTG, OsmanianC, JacksT, HousmanDE, KochCJ, LoweSW, and GiacciaAJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 379: 88–91, 1996.
106.
GrahamCH, ForsdikeJ, FitzgeraldCJ, and Macdonald-GoodfellowS. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer, 80: 617–623, 1999.
GravesEE, VilaltaM, CecicIK, ErlerJT, TranPT, FelsherD, SaylesL, Sweet-CorderoA, LeQT, and GiacciaAJ. Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res, 16: 4843–4852, 2010.
109.
GrayLH, CongerAD, EbertM, HornseyS, and ScottOC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol, 26: 638–648, 1953.
110.
GriffithsJR and RobinsonSP. The OxyLite: a fibre-optic oxygen sensor. Br J Radiol, 72: 627–630, 1999.
111.
GrossMW, KarbachU, GroebeK, FrankoAJ, and Mueller-KlieserW. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int J Cancer, 61: 567–573, 1995.
GrosuAL, SouvatzoglouM, RoperB, DobritzM, WiedenmannN, JacobV, WesterHJ, ReischlG, MachullaHJ, SchwaigerM, MollsM, and PiertM. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys, 69: 541–551, 2007.
114.
HamadaK, SasakiT, KoniPA, NatsuiM, KishimotoH, SasakiJ, YajimaN, HorieY, HasegawaG, NaitoM, MiyazakiJ, SudaT, ItohH, NakaoK, MakTW, NakanoT, and SuzukiA. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev, 19: 2054–2065, 2005.
HarrisonLB, ChadhaM, HillRJ, HuK, and ShashaD. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist, 7: 492–508, 2002.
117.
HavelundBM, HoldgaardPC, RafaelsenSR, MortensenLS, TheilJ, BenderD, PloenJ, SpindlerKL, and JakobsenA. Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer. Nucl Med Commun, 34: 155–161, 2013.
118.
HelczynskaK, KronbladA, JogiA, NilssonE, BeckmanS, LandbergG, and PahlmanS. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res, 63: 1441–1444, 2003.
119.
HendricksonK, PhillipsM, SmithW, PetersonL, KrohnK, and RajendranJ. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol, 101: 369–375, 2011.
120.
HockelM, KnoopC, SchlengerK, VorndranB, BaussmannE, MitzeM, KnapsteinPG, and VaupelP. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol, 26: 45–50, 1993.
121.
HockelM, SchlengerK, AralB, MitzeM, SchafferU, and VaupelP. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res, 56: 4509–4515, 1996.
122.
HockelM and VaupelP. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst, 93: 266–276, 2001.
123.
HollandJP, LewisJS, and DehdashtiF. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med Mol Imaging, 53: 193–200, 2009.
124.
HoogsteenIJ, MarresHA, BussinkJ, van der KogelAJ, and KaandersJH. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head Neck, 29: 591–604, 2007.
125.
HoskinPJ, CarnellDM, TaylorNJ, SmithRE, StirlingJJ, DaleyFM, SaundersMI, BentzenSM, CollinsDJ, d'ArcyJA, and PadhaniAP. Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int J Radiat Oncol Biol Phys, 68: 1065–1071, 2007.
126.
HoskinPJ, SibtainA, DaleyFM, and WilsonGD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer, 89: 1290–1297, 2003.
127.
HudsonCC, LiuM, ChiangGG, OtternessDM, LoomisDC, KaperF, GiacciaAJ, and AbrahamRT. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol, 22: 7004–7014, 2002.
128.
HuiEP, SungFL, YuBK, WongCS, MaBB, LinX, ChanA, WongWL, and ChanAT. Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. Clin Cancer Res, 14: 7080–7087, 2008.
129.
IlieM, MazureNM, HofmanV, AmmadiRE, OrtholanC, BonnetaudC, HavetK, VenissacN, MograbiB, MourouxJ, PouyssegurJ, and HofmanP. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer, 102: 1627–1635, 2010.
130.
IsaAY, WardTH, WestCM, SlevinNJ, and HomerJJ. Hypoxia in head and neck cancer. Br J Radiol, 79: 791–798, 2006.
131.
JanssensGO, RademakersSE, TerhaardCH, DoornaertPA, BijlHP, van den EndeP, ChinA, MarresHA, de BreeR, van der KogelAJ, HoogsteenIJ, BussinkJ, SpanPN, and KaandersJH. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol, 30: 1777–1783, 2012.
132.
JenkinsWT, EvansSM, and KochCJ. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode. Int J Radiat Oncol Biol Phys, 46: 1005–1017, 2000.
133.
JinF, BrockmeierU, OtterbachF, and MetzenE. New insight into the SDF-1/CXCR4 axis in a breast carcinoma model: hypoxia-induced endothelial SDF-1 and tumor cell CXCR4 are required for tumor cell intravasation. Mol Cancer Res, 10: 1021–1031, 2012.
134.
JonathanRA, WijffelsKI, PeetersW, de WildePC, MarresHA, MerkxMA, OosterwijkE, van der KogelAJ, and KaandersJH. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol, 79: 288–297, 2006.
135.
KaandersJH, PopLA, MarresHA, BruasetI, van den HoogenFJ, MerkxMA, and van der KogelAJ. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys, 52: 769–778, 2002.
136.
KaandersJH, WijffelsKI, MarresHA, LjungkvistAS, PopLA, van den HoogenFJ, de WildePC, BussinkJ, RaleighJA, and van der KogelAJ. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res, 62: 7066–7074, 2002.
137.
KapplerM, TaubertH, HolzhausenHJ, ReddemannR, RotS, BeckerA, KuhntT, DellasK, DunstJ, VordermarkD, HansgenG, and BacheM. Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters. Strahlenther Onkol, 184: 393–399, 2008.
138.
KavanaghMC, TsangV, ChowS, KochC, HedleyD, MinkinS, and HillRP. A comparison in individual murine tumors of techniques for measuring oxygen levels. Int J Radiat Oncol Biol Phys, 44: 1137–1146, 1999.
139.
KayamaT, YoshimotoT, FujimotoS, and SakuraiY. Intratumoral oxygen pressure in malignant brain tumor. J Neurosurg, 74: 55–59, 1991.
140.
KhanN, MupparajuS, HouH, WilliamsBB, and SwartzH. Repeated assessment of orthotopic glioma pO(2) by multi-site EPR oximetry: a technique with the potential to guide therapeutic optimization by repeated measurements of oxygen. J Neurosci Methods, 204: 111–117, 2012.
141.
KiedaC, El Hafny-RahbiB, ColletG, Lamerant-FayelN, GrillonC, GuichardA, DulakJ, JozkowiczA, KotlinowskiJ, FylaktakidouKC, VidalA, AuzelouxP, Miot-NoiraultE, BeloeilJC, LehnJM, and NicolauC. Stable tumor vessel normalization with pO(2) increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment. J Mol Med (Berl), 91: 883–899, 2013.
142.
KimSJ, RabbaniZN, DewhirstMW, VujaskovicZ, VollmerRT, SchreiberEG, OosterwijkE, and KelleyMJ. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer, 49: 325–335, 2005.
143.
KimSJ, RabbaniZN, VollmerRT, SchreiberEG, OosterwijkE, DewhirstMW, VujaskovicZ, and KelleyMJ. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res, 10: 7925–7933, 2004.
144.
KochCJ, EvansSM, and LordEM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer, 72: 869–874, 1995.
145.
KochCJ, HahnSM, RockwellKJr., CoveyJM, McKennaWG, and EvansSM. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother Pharmacol, 48: 177–187, 2001.
146.
KochCJ, ScheuermannJS, DivgiC, JudyKD, KachurAV, FreifelderR, ReddinJS, KarpJ, StubbsJB, HahnSM, DriesbaughJ, SmithD, PrendergastS, and EvansSM. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging, 37: 2048–2059, 2010.
147.
KodibagkarVD, WangX, and MasonRP. Physical principles of quantitative nuclear magnetic resonance oximetry. Front Biosci, 13: 1371–1384, 2008.
148.
KohWJ, RaseyJS, EvansML, GriersonJR, LewellenTK, GrahamMM, KrohnKA, and GriffinTW. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys, 22: 199–212, 1992.
149.
KomarG, SeppanenM, EskolaO, LindholmP, GronroosTJ, ForsbackS, SipilaH, EvansSM, SolinO, and MinnH. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med, 49: 1944–1951, 2008.
150.
KoneckySD, ChoeR, CorluA, LeeK, WienerR, SrinivasSM, SafferJR, FreifelderR, KarpJS, HajjiouiN, AzarF, and YodhAG. Comparison of diffuse optical tomography of human breast with whole-body and breast-only positron emission tomography. Med Phys, 35: 446–455, 2008.
151.
KongCS, NarasimhanB, CaoH, KwokS, EricksonJP, KoongA, PourmandN, and LeQT. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys, 74: 553–561, 2009.
152.
KoongAC, MehtaVK, LeQT, FisherGA, TerrisDJ, BrownJM, BastidasAJ, and VierraM. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys, 48: 919–922, 2000.
153.
KumarP, StypinskiD, XiaH, McEwanAJB, MachullaH-J, and WiebeLI. Fluoroazomycin arabinoside (FAZA): synthesis, 2H and 3H-labelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia. J Label Compd Radiopharm, 42: 3–16, 1999.
154.
KunkelM, ReichertTE, BenzP, LehrHA, JeongJH, WieandS, BartensteinP, WagnerW, and WhitesideTL. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer, 97: 1015–1024, 2003.
155.
KunzM and IbrahimSM. Molecular responses to hypoxia in tumor cells. Mol Cancer, 2: 23, 2003.
156.
LaforestR, DehdashtiF, LewisJS, and SchwarzSW. Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging, 32: 764–770, 2005.
157.
LallyBE, RockwellS, FischerDB, CollingridgeDR, PiepmeierJM, and KniselyJP. The interactions of polarographic measurements of oxygen tension and histological grade in human glioma. Cancer J, 12: 461–466, 2006.
158.
LartigauE, Le RidantAM, LambinP, WeegerP, MartinL, SigalR, LusinchiA, LuboinskiB, EschwegeF, and GuichardM. Oxygenation of head and neck tumors. Cancer, 71: 2319–2325, 1993.
159.
LawrenceYR, VikramB, DignamJJ, ChakravartiA, MachtayM, FreidlinB, TakebeN, CurranWJJr., BentzenSM, OkunieffP, ColemanCN, and DickerAP. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst, 105: 11–24, 2012.
160.
LeQT, ChenE, SalimA, CaoH, KongCS, WhyteR, DoningtonJ, CannonW, WakeleeH, TibshiraniR, MitchellJD, RichardsonD, O'ByrneKJ, KoongAC, and GiacciaAJ. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res, 12: 1507–1514, 2006.
161.
LeQT, KongC, LavoriPW, O'ByrneK, ErlerJT, HuangX, ChenY, CaoH, TibshiraniR, DenkoN, GiacciaAJ, and KoongAC. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys, 69: 167–175, 2007.
162.
LeQT, KovacsMS, DorieMJ, KoongA, TerrisDJ, PintoHA, GoffinetDR, NowelsK, BlochD, and BrownJM. Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys, 56: 375–383, 2003.
163.
LeQT, TairaA, BudenzS, Jo DorieM, GoffinetDR, FeeWE, GoodeR, BlochD, KoongA, Martin BrownJ, and PintoHA. Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas. Cancer, 106: 1940–1949, 2006.
164.
LeeCP, PayneGS, OregioniA, RuddleR, TanS, RaynaudFI, EatonD, CampbellMJ, CrossK, HalbertG, TracyM, McNamaraJ, SeddonB, LeachMO, WorkmanP, and JudsonI. A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. Br J Cancer, 101: 1860–1868, 2009.
165.
LeeDJ, CosmatosD, MarcialVA, FuKK, RotmanM, CooperJS, OrtizHG, BeitlerJJ, AbramsRA, CurranWJ, et al. Results of an RTOG phase III trial (RTOG 85–27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys, 32: 567–576, 1995.
166.
LeeDJ, PajakTF, StetzJ, OrderSE, WeissbergJB, and FischerJJ. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79–04). Int J Radiat Oncol Biol Phys, 16: 465–470, 1989.
167.
LeeJW, BaeSH, JeongJW, KimSH, and KimKW. Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med, 36: 1–12, 2004.
168.
LeeNY, MechalakosJG, NehmehS, LinZ, SquireOD, CaiS, ChanK, ZanzonicoPB, GrecoC, LingCC, HummJL, and SchoderH. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys, 70: 2–13, 2008.
169.
LeeSW, BackGM, YiBY, ChoiEK, AhnSD, ShinSS, KimJH, KimSY, LeeBJ, NamSY, ChoiSH, KimSB, ParkJH, LeeKK, ParkSH, and KimJH. Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys, 65: 152–160, 2006.
170.
LewisJS, SharpTL, LaforestR, FujibayashiY, and WelchMJ. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med, 42: 655–661, 2001.
171.
LiM-L, OhJ-T, XIeX, KuG, WangW, LiC, LunguGF, StoicaG, and WangLV. Simultaneous molecular and hypoxia imaging of brain tumors in vivo using spectroscopic photoacoustic tomography. Proc IEEE, 96: 481–489, 2008.
172.
LiSP, PadhaniAR, and MakrisA. Dynamic contrast-enhanced magnetic resonance imaging and blood oxygenation level-dependent magnetic resonance imaging for the assessment of changes in tumor biology with treatment. J Natl Cancer Inst Monogr, 2011: 103–107, 2011.
173.
LiZ, BaoS, WuQ, WangH, EylerC, SathornsumeteeS, ShiQ, CaoY, LathiaJ, McLendonRE, HjelmelandAB, and RichJN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell, 15: 501–513, 2009.
174.
LimAM, CorryJ, CollinsM, PetersL, HicksRJ, D'CostaI, ColemanA, ChuaM, SolomonB, and RischinD. A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. Oral Oncol, 49: 468–474, 2013.
175.
LimAM, RischinD, FisherR, CaoH, KwokK, TruongD, McArthurGA, YoungRJ, GiacciaA, PetersL, and LeQT. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clin Cancer Res, 18: 301–307, 2012.
176.
LinLL, SilvoniemiA, StubbsJB, RenganR, SuilamoS, SolinO, DivgiC, EskolaO, SorgerJM, StabinMG, KachurA, HahnSM, GronroosTJ, ForsbackS, EvansSM, KochCJ, and MinnH. Radiation dosimetry and biodistribution of the hypoxia tracer (1)(8)F-EF5 in oncologic patients. Cancer Biother Radiopharm, 27: 412–419, 2012.
177.
LoncasterJA, CarringtonBM, SykesJR, JonesAP, ToddSM, CooperR, BuckleyDL, DavidsonSE, LogueJP, HunterRD, and WestCM. Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys, 54: 759–767, 2002.
178.
LoncasterJA, HarrisAL, DavidsonSE, LogueJP, HunterRD, WycoffCC, PastorekJ, RatcliffePJ, StratfordIJ, and WestCM. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res, 61: 6394–6399, 2001.
179.
LuX and KangY. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res, 16: 5928–5935, 2010.
180.
LunguGF, LiML, XieX, WangLV, and StoicaG. In vivo imaging and characterization of hypoxia-induced neovascularization and tumor invasion. Int J Oncol, 30: 45–54, 2007.
181.
LyngH, SundforK, TropeC, and RofstadEK. Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. Clin Cancer Res, 6: 1104–1112, 2000.
182.
LyngH, VorrenAO, SundforK, TaksdalI, LienHH, KaalhusO, and RofstadEK. Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA-enhanced MR imaging. J Magn Reson Imaging, 14: 750–756, 2001.
183.
MackPC, RedmanMW, ChanskyK, WilliamsonSK, FarnethNC, LaraPNJr., FranklinWA, LeQT, CrowleyJJ, and GandaraDR. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol, 26: 4771–4776, 2008.
184.
MahyP, De BastM, GallezB, GueuletteJ, KochCJ, ScallietP, and GregoireV. In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors. Radiother Oncol, 67: 53–61, 2003.
185.
MaioneF, MollaF, MedaC, LatiniR, ZentilinL, GiaccaM, SeanoG, SeriniG, BussolinoF, and GiraudoE. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest, 119: 3356–3372, 2009.
186.
MarottaD, KararJ, JenkinsWT, KumanovaM, JenkinsKW, TobiasJW, BaldwinD, HatzigeorgiouA, AlexiouP, EvansSM, AlarconR, MaityA, KochC, and KoumenisC. In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection. Cancer Res, 71: 779–789, 2011.
187.
MatsumotoS, HyodoF, SubramanianS, DevasahayamN, MunasingheJ, HyodoE, GadisettiC, CookJA, MitchellJB, and KrishnaMC. Low-field paramagnetic resonance imaging of tumor oxygenation and glycolytic activity in mice. J Clin Invest, 118: 1965–1973, 2008.
188.
MatsumotoS, YasuiH, BatraS, KinoshitaY, BernardoM, MunasingheJP, UtsumiH, ChoudhuriR, DevasahayamN, SubramanianS, MitchellJB, and KrishnaMC. Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI. Proc Natl Acad Sci U S A, 106: 17898–17903, 2009.
189.
MazzoneM, DettoriD, Leite de OliveiraR, LogesS, SchmidtT, JonckxB, TianYM, LanahanAA, PollardP, Ruiz de AlmodovarC, De SmetF, VinckierS, AragonesJ, DebackereK, LuttunA, WynsS, JordanB, PisacaneA, GallezB, LampugnaniMG, DejanaE, SimonsM, RatcliffeP, MaxwellP, and CarmelietP. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell, 136: 839–851, 2009.
190.
McKennaDJ, McKeownSR, and McKelvey-MartinVJ. Potential use of the comet assay in the clinical management of cancer. Mutagenesis, 23: 183–190, 2008.
191.
MedinaRA and OwenGI. Glucose transporters: expression, regulation and cancer. Biol Res, 35: 9–26, 2002.
192.
MengX, KongFM, and YuJ. Implementation of hypoxia measurement into lung cancer therapy. Lung Cancer, 75: 146–150, 2012.
193.
MoellerBJ, CaoY, LiCY, and DewhirstMW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell, 5: 429–441, 2004.
194.
MortensenLS, BuskM, NordsmarkM, JakobsenS, TheilJ, OvergaardJ, and HorsmanMR. Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: a preclinical study. Radiother Oncol, 99: 418–423, 2011.
195.
MortensenLS, BuusS, NordsmarkM, BentzenL, MunkOL, KeidingS, and OvergaardJ. Identifying hypoxia in human tumors: a correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode. Acta Oncol, 49: 934–940, 2010.
196.
MortensenLS, JohansenJ, KallehaugeJ, PrimdahlH, BuskM, LassenP, AlsnerJ, SorensenBS, ToustrupK, JakobsenS, PetersenJ, PetersenH, TheilJ, NordsmarkM, and OvergaardJ. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol, 105: 14–20, 2012.
197.
MottramJC. A factor of importance in the radio sensitivity of tumours. Br J Radiol, 9: 606–614, 1936.
198.
MovsasB, ChapmanJD, HorwitzEM, PinoverWH, GreenbergRE, HanlonAL, IyerR, and HanksGE. Hypoxic regions exist in human prostate carcinoma. Urology, 53: 11–18, 1999.
199.
NehmehSA, LeeNY, SchroderH, SquireO, ZanzonicoPB, ErdiYE, GrecoC, MagerasG, PhamHS, LarsonSM, LingCC, and HummJL. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys, 70: 235–242, 2008.
200.
NewboldK, CastellanoI, Charles-EdwardsE, MearsD, SohaibA, LeachM, Rhys-EvansP, ClarkeP, FisherC, HarringtonK, and NuttingC. An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer. Int J Radiat Oncol Biol Phys, 74: 29–37, 2009.
201.
NordsmarkM, BentzenSM, RudatV, BrizelD, LartigauE, StadlerP, BeckerA, AdamM, MollsM, DunstJ, TerrisDJ, and OvergaardJ. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol, 77: 18–24, 2005.
202.
NordsmarkM, EriksenJG, GebskiV, AlsnerJ, HorsmanMR, and OvergaardJ. Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol, 83: 389–397, 2007.
203.
NordsmarkM, LoncasterJ, Aquino-ParsonsC, ChouSC, GebskiV, WestC, LindegaardJC, HavsteenH, DavidsonSE, HunterR, RaleighJA, and OvergaardJ. The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol, 80: 123–131, 2006.
204.
NordsmarkM and OvergaardJ. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol, 57: 39–43, 2000.
205.
NordsmarkM and OvergaardJ. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol, 43: 396–403, 2004.
206.
NordsmarkM, OvergaardM, and OvergaardJ. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol, 41: 31–39, 1996.
207.
NyflotMJ, HarariPM, YipS, PerlmanSB, and JerajR. Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx. Radiother Oncol, 105: 36–40, 2012.
208.
OkamotoS, ShigaT, YasudaK, ItoYM, MagotaK, KasaiK, KugeY, ShiratoH, and TamakiN. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med, 54: 201–207, 2013.
209.
OlivePL, DurandRE, JacksonSM, Le RicheJC, LuoC, MaR, McLarenDB, Aquino-ParsonsC, ThomsonTA, and TrotterT. The comet assay in clinical practice. Acta Oncol, 38: 839–844, 1999.
210.
OlivePL, DurandRE, Le RicheJ, OlivottoIA, and JacksonSM. Gel electrophoresis of individual cells to quantify hypoxic fraction in human breast cancers. Cancer Res, 53: 733–736, 1993.
211.
OronskyBT, KnoxSJ, and ScicinskiJ. Six degrees of separation: the oxygen effect in the development of radiosensitizers. Transl Oncol, 4: 189–198, 2011.
212.
This reference has been deleted.
213.
OvergaardJ. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res, 6: 509–518, 1994.
214.
OvergaardJ. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck—a systematic review and meta-analysis. Radiother Oncol, 100: 22–32, 2011.
215.
OvergaardJ, EriksenJG, NordsmarkM, AlsnerJ, and HorsmanMR. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol, 6: 757–764, 2005.
216.
OvergaardJ, HansenHS, OvergaardM, BastholtL, BerthelsenA, SpechtL, LindelovB, and JorgensenK. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5–85. Radiother Oncol, 46: 135–146, 1998.
217.
OvergaardJ, HansenHS, SpechtL, OvergaardM, GrauC, AndersenE, BentzenJ, BastholtL, HansenO, JohansenJ, AndersenL, and EvensenJF. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet, 362: 933–940, 2003.
218.
PetersL and RischinD. Elusive goal of targeting tumor hypoxia for therapeutic gain. J Clin Oncol, 30: 1741–1743, 2012.
PogueBW, PaulsenKD, O'HaraJA, WilmotCM, and SwartzHM. Estimation of oxygen distribution in RIF-1 tumors by diffusion model-based interpretation of pimonidazole hypoxia and eppendorf measurements. Radiat Res, 155: 15–25, 2001.
221.
PoppleRA, OveR, and ShenS. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys, 54: 921–927, 2002.
222.
PostemaEJ, McEwanAJ, RiaukaTA, KumarP, RichmondDA, AbramsDN, and WiebeLI. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging, 36: 1565–1573, 2009.
223.
RademakersSE, LokJ, van der KogelAJ, BussinkJ, and KaandersJH. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer, 11: 167, 2011.
224.
RajendranJG, MankoffDA, O'SullivanF, PetersonLM, SchwartzDL, ConradEU, SpenceAM, MuziM, FarwellDG, and KrohnKA. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res, 10: 2245–2252, 2004.
225.
RajendranJG, SchwartzDL, O'SullivanJ, PetersonLM, NgP, ScharnhorstJ, GriersonJR, and KrohnKA. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res, 12: 5435–5441, 2006.
226.
RaleighJA, ChouSC, ArteelGE, and HorsmanMR. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res, 151: 580–589, 1999.
227.
RaseyJS, GrunbaumZ, MageeS, NelsonNJ, OlivePL, DurandRE, and KrohnKA. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res, 111: 292–304, 1987.
228.
RischinD, FisherR, PetersL, CorryJ, and HicksR. Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. Int J Radiat Oncol Biol Phys, 69: S61–S63, 2007.
229.
RischinD, HicksRJ, FisherR, BinnsD, CorryJ, PorcedduS, and PetersLJ. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol, 24: 2098–2104, 2006.
230.
RischinD, PetersL, FisherR, MacannA, DenhamJ, PoulsenM, JacksonM, KennyL, PennimentM, CorryJ, LambD, and McClureB. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol, 23: 79–87, 2005.
231.
RischinD, PetersL, HicksR, HughesP, FisherR, HartR, SextonM, D'CostaI, and von RoemelingR. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol, 19: 535–542, 2001.
232.
RischinD, PetersLJ, O'SullivanB, GiraltJ, FisherR, YuenK, TrottiA, BernierJ, BourhisJ, RingashJ, HenkeM, and KennyL. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol, 28: 2989–2995, 2010.
233.
Roizin-TowleL and HallEJ. The effect of bleomycin on aerated and hypoxic cells in vitro, in combination with irradiation. Int J Radiat Oncol Biol Phys, 5: 1491–1494, 1979.
234.
RolnyC, MazzoneM, TuguesS, LaouiD, JohanssonI, CoulonC, SquadritoML, SeguraI, LiX, KnevelsE, CostaS, VinckierS, DresselaerT, AkerudP, De MolM, SalomakiH, PhillipsonM, WynsS, LarssonE, BuysschaertI, BotlingJ, HimmelreichU, Van GinderachterJA, De PalmaM, DewerchinM, Claesson-WelshL, and CarmelietP. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell, 19: 31–44, 2011.
RudatV, StadlerP, BeckerA, VanselowB, DietzA, WannenmacherM, MollsM, DunstJ, and FeldmannHJ. Predictive value of the tumor oxygenation by means of pO2 histography in patients with advanced head and neck cancer. Strahlenther Onkol, 177: 462–468, 2001.
237.
RudatV, VanselowB, WollensackP, BettscheiderC, Osman-AhmetS, EbleMJ, and DietzA. Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer. Radiother Oncol, 57: 31–37, 2000.
238.
RumseyWL, VanderkooiJM, and WilsonDF. Imaging of phosphorescence: a novel method for measuring oxygen distribution in perfused tissue. Science, 241: 1649–1651, 1988.
239.
RussellJ, CarlinS, BurkeSA, WenB, YangKM, and LingCC. Immunohistochemical detection of changes in tumor hypoxia. Int J Radiat Oncol Biol Phys, 73: 1177–1186, 2009.
240.
SamouilovA, CaiaGL, KesselringE, PetryakovS, WasowiczT, and ZweierJL. Development of a hybrid EPR/NMR coimaging system. Magn Reson Med, 58: 156–166, 2007.
241.
ScholbachT, ScholbachJ, KrombachGA, GagelB, ManeschiP, and Di MartinoE. New method of dynamic color doppler signal quantification in metastatic lymph nodes compared to direct polarographic measurements of tissue oxygenation. Int J Cancer, 114: 957–962, 2005.
242.
SeeberLM, HorreeN, VooijsMA, HeintzAP, van der WallE, VerheijenRH, and van DiestPJ. The role of hypoxia inducible factor-1alpha in gynecological cancer. Crit Rev Oncol Hematol, 78: 173–184, 2011.
243.
SeiwertTY, SalamaJK, and VokesEE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol, 4: 156–171, 2007.
244.
SemenzaGL. Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med, 41: 79–83, 2002.
245.
SemenzaGL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 3: 721–732, 2003.
246.
SemenzaGL. Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning. Biochim Biophys Acta, 1813: 1263–1268, 2011.
247.
SemenzaGL. Oxygen sensing, homeostasis, and disease. N Engl J Med, 365: 537–547, 2011.
248.
SeveringhausJW, WeiskopfRB, NishimuraM, and BradleyAF. Oxygen electrode errors due to polarographic reduction of halothane. J Appl Physiol, 31: 640–642, 1971.
249.
ShaoQ, MorgounovaE, JiangC, ChoiJ, BischofJ, and AshkenaziS. In vivo photoacoustic lifetime imaging of tumor hypoxia in small animals. J Biomed Opt, 18: 076019, 2013.
250.
SouvatzoglouM, GrosuAL, RoperB, KrauseBJ, BeckR, ReischlG, PicchioM, MachullaHJ, WesterHJ, and PiertM. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging, 34: 1566–1575, 2007.
251.
StadlerP, BeckerA, FeldmannHJ, HansgenG, DunstJ, WurschmidtF, and MollsM. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys, 44: 749–754, 1999.
252.
StanzK, LiuB, MinsongC, ReineckeD, MillerK, and KrugerR. Photoacoustic spectoscopic imaging of intra-tumor heterogeneity and molecular identification. SPIE Proc, 6086: 605–608, 2006.
253.
StoneHB, BrownJM, PhillipsTL, and SutherlandRM. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19–20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat Res, 136: 422–434, 1993.
254.
SubarskyP and HillRP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis, 20: 237–250, 2003.
255.
SullivanR and GrahamCH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev, 26: 319–331, 2007.
256.
TanakaN, KatoH, InoseT, KimuraH, FariedA, SohdaM, NakajimaM, FukaiY, MiyazakiT, MasudaN, FukuchiM, and KuwanoH. Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer, 99: 1468–1475, 2008.
257.
TannockIF. Conventional cancer therapy: promise broken or promise delayed?. Lancet, 351Suppl 2: SII9–SII16, 1998.
258.
TatumJL, KelloffGJ, GilliesRJ, ArbeitJM, BrownJM, ChaoKS, ChapmanJD, EckelmanWC, FylesAW, GiacciaAJ, HillRP, KochCJ, KrishnaMC, KrohnKA, LewisJS, MasonRP, MelilloG, PadhaniAR, PowisG, RajendranJG, RebaR, RobinsonSP, SemenzaGL, SwartzHM, VaupelP, YangD, CroftB, HoffmanJ, LiuG, StoneH, and SullivanD. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol, 82: 699–757, 2006.
259.
TaylorNJ, BaddeleyH, GoodchildKA, PowellME, ThoumineM, CulverLA, StirlingJJ, SaundersMI, HoskinPJ, PhillipsH, PadhaniAR, and GriffithsJR. BOLD MRI of human tumor oxygenation during carbogen breathing. J Magn Reson Imaging, 14: 156–163, 2001.
260.
TeicherBA. Hypoxia and drug resistance. Cancer Metastasis Rev, 13: 139–168, 1994.
261.
TeicherBA, HoldenSA, al-AchiA, and HermanTS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res, 50: 3339–3344, 1990.
262.
TerrisDJ. Head and neck cancer: the importance of oxygen. Laryngoscope, 110: 697–707, 2000.
263.
ThomlinsonRH and GrayLH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer, 9: 539–549, 1955.
264.
ThorwarthD, EschmannSM, HolznerF, PaulsenF, and AlberM. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol, 80: 151–156, 2006.
265.
ThorwarthD, EschmannSM, PaulsenF, and AlberM. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys, 68: 291–300, 2007.
266.
Toma-DasuI, UhrdinJ, AntonovicL, DasuA, NuytsS, DirixP, HaustermansK, and BrahmeA. Dose prescription and treatment planning based on FMISO-PET hypoxia. Acta Oncol, 51: 222–230, 2012.
267.
TongRT, BoucherY, KozinSV, WinklerF, HicklinDJ, and JainRK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res, 64: 3731–3736, 2004.
268.
ToustrupK, SorensenBS, LassenP, WiufC, AlsnerJ, and OvergaardJ. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol, 102: 122–129, 2012.
269.
TranLB, BolA, LabarD, JordanB, MagatJ, MignionL, GregoireV, and GallezB. Hypoxia imaging with the nitroimidazole 18F-FAZA PET tracer: a comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry. Radiother Oncol, 105: 29–35, 2012.
270.
TurakaA, BuyyounouskiMK, HanlonAL, HorwitzEM, GreenbergRE, and MovsasB. Hypoxic prostate/muscle PO2 ratio predicts for outcome in patients with localized prostate cancer: long-term results. Int J Radiat Oncol Biol Phys, 82: e433–e439, 2012.
271.
ValableS, PetitE, RousselS, MarteauL, ToutainJ, DivouxD, SobrioF, DelamareJ, BarreL, and BernaudinM. Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model. Nucl Med Biol, 38: 781–793, 2011.
272.
van LoonJ, JanssenMH, OllersM, AertsHJ, DuboisL, HochstenbagM, DingemansAM, LalisangR, BransB, WindhorstB, van DongenGA, KolbH, ZhangJ, De RuysscherD, and LambinP. PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging, 37: 1663–1668, 2010.
273.
VanderkooiJM and WilsonDF. A new method for measuring oxygen concentration in biological systems. Adv Exp Med Biol, 200: 189–193, 1986.
274.
VaupelP. The role of hypoxia-induced factors in tumor progression. Oncologist, 9Suppl 5: 10–17, 2004.
275.
VaupelP. Pathophysiology of Solid Tumors. Berlin, Heidelberg: Springer-Verlag, 2009.
276.
VaupelP and HarrisonL. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist, 9Suppl 5: 4–9, 2004.
277.
VaupelP, HockelM, and MayerA. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal, 9: 1221–1235, 2007.
278.
VaupelP, MayerA, BriestS, and HockelM. Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res, 63: 7634–7637, 2003.
279.
VaupelP, SchlengerK, KnoopC, and HockelM. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res, 51: 3316–3322, 1991.
280.
VaupelP, ThewsO, and HoeckelM. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol, 18: 243–259, 2001.
281.
VergisR, CorbishleyCM, NormanAR, BartlettJ, JhavarS, BorreM, HeebollS, HorwichA, HuddartR, KhooV, EelesR, CooperC, SydesM, DearnaleyD, and ParkerC. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol, 9: 342–351, 2008.
282.
von PawelJ, von RoemelingR, GatzemeierU, BoyerM, ElissonLO, ClarkP, TalbotD, ReyA, ButlerTW, HirshV, OlverI, BergmanB, AyoubJ, RichardsonG, DunlopD, ArcenasA, VescioR, VialletJ, and TreatJ. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol, 18: 1351–1359, 2000.
283.
VordermarkD and BrownJM. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?. Strahlenther Onkol, 179: 801–811, 2003.
284.
WangJ, FoehrenbacherA, SuJ, PatelR, HayMP, HicksKO, and WilsonWR. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia. Clin Cancer Res, 18: 1684–1695, 2012.
285.
WassermanTH, LeeDJ, CosmatosD, ColemanN, PhillipsT, DavisL, MarcialV, and StetzJ. Clinical trials with etanidazole (SR-2508) by the Radiation Therapy Oncology Group (RTOG). Radiother Oncol, 20Suppl 1: 129–135, 1991.
286.
WeberGF. The cancer biomarker osteopontin: combination with other markers. Cancer Genomics Proteomics, 8: 263–288, 2011.
287.
WiedenmannN, HentschelM, BucherS, MixM, AdebahrS, OffermannC, NestleU, WeberW, and GrosuAL. Dynamics of tumor hypoxia in patients undergoing radiochemotherapy for head and neck cancer evaluated with serial 18F-fluoromisonidazole PET. Int J Radiat Oncol, 78: S703, 2010.
288.
WilliamsBB, KhanN, ZakiB, HartfordA, ErnstoffMS, and SwartzHM. Clinical electron paramagnetic resonance (EPR) oximetry using India ink. Adv Exp Med Biol, 662: 149–156, 2010.
289.
WilsonDF, LeeWM, MakonnenS, AprelevaS, and VinogradovSA. Oxygen pressures in the interstitial space of skeletal muscle and tumors in vivo. Adv Exp Med Biol, 614: 53–62, 2008.
290.
WinklerF, KozinSV, TongRT, ChaeSS, BoothMF, GarkavtsevI, XuL, HicklinDJ, FukumuraD, di TomasoE, MunnLL, and JainRK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell, 6: 553–563, 2004.
291.
WolfM, FerrariM, and QuaresimaV. Progress of near-infrared spectroscopy and topography for brain and muscle clinical applications. J Biomed Opt, 12: 062104, 2007.
292.
WoodsML, KochCJ, and LordEM. Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies. Int J Radiat Oncol Biol Phys, 34: 93–101, 1996.
293.
WykoffCC, BeasleyNJ, WatsonPH, TurnerKJ, PastorekJ, SibtainA, WilsonGD, TurleyH, TalksKL, MaxwellPH, PughCW, RatcliffePJ, and HarrisAL. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res, 60: 7075–7083, 2000.
294.
XiaY, ChoiHK, and LeeK. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem, 49: 24–40, 2012.
295.
YasuiH, MatsumotoS, DevasahayamN, MunasingheJP, ChoudhuriR, SaitoK, SubramanianS, MitchellJB, and KrishnaMC. Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice. Cancer Res, 70: 6427–6436, 2010.
296.
ZhongH, ChilesK, FeldserD, LaughnerE, HanrahanC, GeorgescuMM, SimonsJW, and SemenzaGL. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res, 60: 1541–1545, 2000.
297.
ZhongH, De MarzoAM, LaughnerE, LimM, HiltonDA, ZagzagD, BuechlerP, IsaacsWB, SemenzaGL, and SimonsJW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res, 59: 5830–5835, 1999.
298.
ZhuY, DenhardtDT, CaoH, SutphinPD, KoongAC, GiacciaAJ, and LeQT. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene, 24: 6555–6563, 2005.
299.
ZiemerLS, EvansSM, KachurAV, ShumanAL, CardiCA, JenkinsWT, KarpJS, AlaviA, DolbierWRJr., and KochCJ. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imaging, 30: 259–266, 2003.
300.
ZiemerLS, KochCJ, MaityA, MagarelliDP, HoranAM, and EvansSM. Hypoxia and VEGF mRNA expression in human tumors. Neoplasia, 3: 500–508, 2001.
301.
ZiemerLS, LeeWM, VinogradovSA, SehgalC, and WilsonDF. Oxygen distribution in murine tumors: characterization using oxygen-dependent quenching of phosphorescence. J Appl Physiol, 98: 1503–1510, 2005.
302.
ZimnyM, GagelB, DiMartinoE, HamacherK, CoenenHH, WesthofenM, EbleM, BuellU, and ReinartzP. FDG—a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging, 33: 1426–1431, 2006.
303.
ZipsD, ZophelK, AbolmaaliN, PerrinR, AbramyukA, HaaseR, AppoldS, SteinbachJ, KotzerkeJ, and BaumannM. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol, 105: 21–28, 2012.
